Overview

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

Status:
Completed
Trial end date:
2018-04-12
Target enrollment:
Participant gender:
Summary
This study will compare treatment emergent incidence rate of ADA between TPI-120 and US licensed Neulasta in normal healthy adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Adello Biologics, LLC
Collaborator:
Celerion